> Detailanzeige

Nelken, Brigitte; Cave, Helene; Leverger, Guy; Galambrun, Claire; Plat, Genevieve; Schmitt, Claudine; Thomas, Caroline; Vérité, Cécile; Brethon, Benoit; Gandemer, Virginie; Bertrand, Yves; Baruchel, André; Rohrlich, Pierre

A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee)
  • Beteiligte: Nelken, Brigitte; Cave, Helene; Leverger, Guy; Galambrun, Claire; Plat, Genevieve; Schmitt, Claudine; Thomas, Caroline; Vérité, Cécile; Brethon, Benoit; Gandemer, Virginie; Bertrand, Yves; Baruchel, André; Rohrlich, Pierre
  • Erschienen: Wiley, 2016
  • Erschienen in: Pediatric Blood & Cancer
  • Sprache: Englisch
  • DOI: 10.1002/pbc.25751
  • ISSN: 1545-5017; 1545-5009
  • Schlagwörter: Oncology ; Hematology ; Pediatrics, Perinatology and Child Health
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Background</jats:title><jats:p>Current outcome of very early relapse of acute lymphoblastic leukemia (ALL) in children remains poor. As a single agent, clofarabine provided a response rate of 26% in childhood ALL second relapse and, in combination with cyclophosphamide and etoposide, a 44% complete remission and complete remission without platelet recovery (CR+CRp) rate. Further multi‐drug combinations need to be investigated. We used the VANDA regimen as a template, cytarabine being replaced by clofarabine.</jats:p></jats:sec><jats:sec><jats:title>Patients and methods</jats:title><jats:p>A phase I study combining escalating doses of clofarabine (25% increments from 20 to 40 mg/m<jats:sup>2</jats:sup>/d) with fixed doses of mitoxantrone, etoposide, asparaginase, and dexamethasone was undertaken in children presenting with very early or second or post‐transplant ALL relapse.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Twenty patients were enrolled, 19 were evaluable. Four patients had previously been allografted. Dose‐limiting toxicity (DLT) appeared at dose level 3 (32 mg/m<jats:sup>2</jats:sup>), one out of six patients experienced a liver DLT. At dose level 4 (40 mg/m<jats:sup>2</jats:sup>), four DLT occurred (two fungal infection and two liver DLT). The maximum tolerated dose (MTD) of clofarabine was thus determined to be 32 mg/m<jats:sup>2</jats:sup>. There was no toxic death. Eleven (57.9%) patients achieved a CR. Six patients proceeded to allogeneic stem cell transplantation.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Clofarabine MTD was 32 mg/m<jats:sup>2</jats:sup>/d in this combination which appeared feasible and effective in this population. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.</jats:p></jats:sec>